News · Yahoo Finance

September 2026 Quarterly Results

Westgold (ASX: WGX) reported Q1 FY27 (quarter ended 30 September 2026) gold production of 98.4koz at an AISC of $2,912/oz, versus 98.9koz at $2,802/oz in Q4 FY26. The company recorded no lost time injuries, lifted ore stockpiles 51% to 696kt, and reaffirmed FY27 guidance of 385–425koz. An AISC margin of $3,117/oz delivered $292M in mine operating cash flow and an underlying Treasury build of $251M, lifting cash, bullion and liquid investments to $1,040M, and the company remains debt free and unhedged. Group Ore Reserves rose 41% to 4.1Moz, a $50M on-market buy-back was approved with $22M already bought, and a revised policy sets a minimum annual return of 3 cents per share.

Summary written by Upside AI from the original article. Read the source for full details.

Read the original on Yahoo Finance ↗

Related news

Related markets

Gold →

Latest news

  • 'Time Bomb' in Southeast Asia's Only Trillion-Dollar Economy: Stocks Plunge, Investors Flee, Unemployed Youth Turn to Motorbike Taxis, Former Minister Warns Economy Nears Brink

    In Southeast Asia's only trillion-dollar economy, a 28-year-old IT graduate now works as a motorbike ride-hailing driver earning about $220 a month, while the middle class has shrunk roughly 19% from its peak and youth unemployment sits near 17%. After MSCI warned it could drop the market from its reference indexes, Indonesian stocks fell more than 11% on October 16, their steepest one-day drop since the 1998 Asian financial crisis, and slid nearly 4% more on October 19. High oil prices, rising U.S. interest rates and costly subsidies, such as free meals for over 80 million students at an estimated $30 billion a year, are adding pressure on the rupiah and the budget. Ferry Latuhihin, former chief economist at International Indonesia Bank, calls the situation a 'time bomb', while former trade minister Thomas Lembong warns the country is getting ever closer to the brink. Phillip Wool of Rayliant says the risk is concentrated in Indonesia.

    CafeF·▼ VNINDEX
  • SpaceX, Tesla Form Independent Committees To Explore Merger: Elon Musk Says Deal ‘Not A Certainty’

    SpaceX and Tesla have formed special committees of independent directors to explore a possible combination, Elon Musk said on SpaceX's third-quarter earnings call. Musk, who leads both firms, is excluded from the talks, and the committees have not agreed on any terms; he said a merger is not a certainty and would need broad shareholder support, with Tesla approval requiring a majority of all outstanding shares. SpaceX reported third-quarter revenue of $14.58 billion versus an estimated $13 billion and EPS of $0.35 against $0.13 expected, driven by superintelligence segment growth. It had $63 billion in backlog, of which $42 billion is expected to convert within a year, and guided to $35–$40 billion in fourth-quarter capex and $33–$37 billion in first-quarter 2027 revenue. SPCX closed near $148, above its $135 IPO price but below its all-time high near $226.

    Yahoo Finance·• TSLA
  • Could Investing $5,000 in Redwire Stock Make You a Millionaire?

    Redwire shares, which listed via a SPAC merger, are down about 21% over the past five years despite brief rallies. In the second quarter, revenue jumped roughly 89% to a record $117.1 million, and the backlog reached $542.1 million. The defense technology segment, boosted by the 2025 acquisition of Edge Autonomy, surged to $61.9 million, and the article argues this business will drive most of future growth. Gross margin improved from negative 30.9% to 27.8%, while the operating loss narrowed from $91.9 million to $22.1 million. The article notes Redwire is still far from sustainable profitability and that the trend may depend on sustaining performance after acquisitions.

    Yahoo Finance·
  • Wall Street diverges Tuesday , industrials advance , techs slip

    Wall Street diverged on Tuesday, with industrials rising sharply while tech lagged, although AI stocks firmed after recent sell-offs. The S&P 500 closed at 7,712.75, up 0.29%, while the Dow Jones Industrial Average rose 1.02% to 52,497.42 and the Nasdaq Composite slipped 0.02% to 26,424.82. Direxion's Jake Behan said the market had tolerated higher rates because of the AI growth story, but that relationship began to be tested last week, and upcoming hyperscaler reports on ROI, data centre spending and 2027 capex would matter more than headline earnings. The U.S. dollar weakened against major currencies, European indices mostly fell, and Asian markets diverged: Japan's Nikkei 225 dropped 1.30% and South Korea's KOSPI fell 3.73%, while Indonesia's IDX Composite jumped 5.65%.

    hongkongherald.com·▼ QQQ• SPY
  • Wall Street diverges Tuesday , industrials advance , techs slip

    Wall Street diverged on Tuesday, with industrials rising sharply while tech lagged, although AI stocks firmed after recent sell-offs. The S&P 500 closed at 7,712.75, up 0.29%, while the Dow Jones Industrial Average rose 1.02% to 52,497.42 and the Nasdaq Composite slipped 0.02% to 26,424.82. Direxion's Jake Behan said the market had tolerated higher rates because of the AI growth story, but that relationship began to be tested last week, and upcoming hyperscaler reports on ROI, data centre spending and 2027 capex would matter more than headline earnings. The U.S. dollar weakened against major currencies, European indices mostly fell, and Asian markets diverged: Japan's Nikkei 225 dropped 1.30% and South Korea's KOSPI fell 3.73%, while Indonesia's IDX Composite jumped 5.65%.

    saltlakecitysun.com·▼ QQQ• SPY
  • Amgen vs . Bristol Myers Squibb : Which Healthcare Stock Is a Better Buy in 2026 ?

    This comparison of Amgen (AMGN) and Bristol Myers Squibb (BMY) uses FY 2025 financials. Amgen reported revenue of about $36.8 billion, up roughly 10%, net income of about $7.7 billion (net margin around 21%) and free cash flow near $8.1 billion; BMY posted revenue of about $48.2 billion, nearly flat, net income of about $7.1 billion (net margin about 14.6%) and free cash flow of about $12.8 billion. The article notes Amgen faces drug pricing pressure, an ongoing IRS tax dispute and biosimilar competition, while BMY depends heavily on Eliquis and faces generic competition and government pricing constraints. It concludes BMY trades at a significantly lower valuation than Amgen, though much of its expected difficulty may already be priced in.

    fool.com·

All news →

Get the briefing on Telegram or Zalo

Join the Upside Telegram channel or Zalo group for the Vietnam stocks and gold briefing at 8:00 and 19:00 (Vietnam time) on trading days, plus a weekly wrap on Saturday morning.